case series:Decitabine

4 trials

Sponsors

The First Hospital of Lanzhou University, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences

Conditions

Chronic Myelomonocytic Leukaemia (CMML)Myelodysplastic Syndrome (MDS)Myelodysplastic SyndromesMyelodysplastic syndrome, Elderly acute myeloid leukemia

Phase 4

A single-center, prospective study for lower dose Decitabine in subjects with intermediate-2 and high risk Myelodysplastic Syndrome (MDS)

Active, not recruitingChiCTR-ONC-13004271

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical SciencesMyelodysplastic Syndrome (MDS)

Start: 2014-02-01Updated: 2017-04-18

A multicenter, prospective study for lower dose Decitabine in subjects with Chronic Myelomonocytic Leukaemia (CMML)

Active, not recruitingChiCTR-OPC-17010598

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical SciencesChronic Myelomonocytic Leukaemia (CMML)

Start: 2017-03-01Updated: 2017-04-18

An open-lab, multicenter, prospective study for reduced dosage Decitabine in subjects with Myelodysplastic Syndromes-Refractory Anemia with Excess Blasts (MDS-RAEB)

Active, not recruitingChiCTR-OPC-17011122

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical SciencesMyelodysplastic Syndromes

Start: 2017-05-01Updated: 2017-04-18

Clinical research for decitabine in maintenance therapy for intermediate/high-risk myelodysplastic syndrome and elderly acute myeloid leukemia.

Active, not recruitingChiCTR1900021030

The First Hospital of Lanzhou UniversityMyelodysplastic syndrome, Elderly acute myeloid leukemia

Start: 2019-03-01Updated: 2019-01-28